

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
The University of Texas M.D. Anderson Cancer Center	04/27/1998
RECEIVING PARTY DATA	
Name:	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government
Street Address:	NIH Division of Extramural Inventions and Technology Resources (DEITR)
Internal Address:	6705 Rockledge Drive, Suite 310, MSC 7980
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20892-7980
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	5286739
CORRESPONDENCE DATA	
Fax Number:	(301)480-0272
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	edison@nih.gov
Correspondent Name:	Director, DEITR
Address Line 1:	NIH, 6705 Rockledge Drive, Suite 310
Address Line 2:	MSC 7980
Address Line 4:	Bethesda, MARYLAND 20892-7980
NAME OF SUBMITTER:	Director, DEITR, NIH
Total Attachments: 1 source=5286739-p0001 - p0004#page4.tif	

LICENSE TO THE UNITED STATES GOVERNMENT

This instrument confers to the United States Government, as represented by the National Institute of Health, a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on its behalf throughout the world the following subject invention:

Invention Title : "Parenteral Formulations for the Inhibition of Systemic Hypotension Associated with Nitric Oxide Production of Endothelial Derived Relaxing Factor" UTSC:202

Inventor(s) : Robert G. Kilbourn, M.D., Ph.D.
Owen W. Griffith

Patent Application


Serial No. : 07/767,265
Filing Date : 9/27/91

Country :
(If other than US)

This subject invention was conceived or first actually reduced to practice in performance of government-funded project National Institutes of Health grant/contract No. DK-37116.

Principal rights to this subject invention have been left with the Licensor, The University of Texas M.D. Anderson Cancer Center, subject to the provisions of 37 CFR 401 and 45 CFR 8.

Signed:



David J. Bachrach
Executive Vice President
for Administration and Finance

PATENT